The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity
Open accessAbstract
BACKGROUND: Bleeding is a complication of treatment with factor Xa inhibitors, but there are no specific agents for the reversal of the effects of these drugs. Andexanet is designed to reverse the anticoagulant effects of factor Xa inhibitors. METHODS: Healthy older volunteers were given 5 mg of apixaban twice daily or 20 mg of rivaroxaban daily. For each factor Xa inhibitor, a two-part randomized placebo-controlled study was conducted to evaluate andexanet administered as a bolus or as a bolus plus a 2-hour infusion. The primary outcome was the mean percent change in anti-factor Xa activity, which is a measure of factor Xa inhibition by the anticoagulant. RESULTS: Among the apixaban-treated participants, anti-factor Xa activity was reduced by 94% among those who received an andexanet bolus (24 participants), as compared with 21% among those who received placebo (9 participants) (P<0.001), and unbound apixaban concentration was reduced by 9.3 ng per milliliter versus 1.9 ng per milliliter (P<0.001); thrombin generation was fully restored in 100% versus 11% of the participants (P<0.001) within 2 to 5 minutes. Among the rivaroxaban-treated participants, anti-factor Xa activity was reduced by 92% among those who received an andexanet bolus (27 participants), as compared with 18% among those who received placebo (14 participants) (P<0.001), and unbound rivaroxaban concentration was reduced by 23.4 ng per milliliter versus 4.2 ng per milliliter (P<0.001); thrombin generation was fully restored in 96% versus 7% of the participants (P<0.001). These effects were sustained when andexanet was administered as a bolus plus an infusion. In a subgroup of participants, transient increases in levels of d-dimer and prothrombin fragments 1 and 2 were observed, which resolved within 24 to 72 hours. No serious adverse or thrombotic events were reported. CONCLUSIONS: Andexanet reversed the anticoagulant activity of apixaban and rivaroxaban in older healthy participants within minutes after administration and for the duration of infusion, without evidence of clinical toxic effects. (Funded by Portola Pharmaceuticals and others; ANNEXA-A and ANNEXA-R ClinicalTrials.gov numbers, NCT02207725 and NCT02220725.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Andexanet alpha, a modified recombinant human factor Xa that lacks enzymatic activity, reverses the anticoagulant activity of apixaban and rivaroxaban in healthy probands within minutes after administration and for the duration of infusion, with a transient increase in markers of coagulation activity of uncertain clinical relevance.508”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [508]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Edoxaban versus warfarin in patients with atrial fibrillation
Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., Waldo, A. L., Ezekowitz, M. D., Weitz, J. I., Špinar, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310907 · Cited by 5,164
Idarucizumab for Dabigatran Reversal
Pollack, C. V., Reilly, P. A., Eikelboom, J., Glund, S., Verhamme, P., Bernstein, R. A., Dubiel, R., Huisman, M. V., Hylek, E. M., Kamphuisen, P. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502000 · Cited by 1,552
Idarucizumab for dabigatran reversal
Garrett, A. D., PharmD, & Bcps (2015) · Cited by 1,169
Lu, G., DeGuzman, F. R., Hollenbach, S. J., Karbarz, M. J., Abe, K. Y., Lee, G., Luan, P., Hutchaleelaha, A., Inagaki, M., Conley, P. B., et al. (2013) · Nature Medicine · doi:10.1038/nm.3102 · Cited by 700
Self-citationProbability Tables for Individual Comparisons by Ranking Methods
Wilcoxon, F. (1947) · Biometrics · doi:10.2307/3001946 · Cited by 578
MicroRNA-328 Contributes to Adverse Electrical Remodeling in Atrial Fibrillation
Lu, Y., Zhang, Y., Wang, N., Pan, Z., Gao, X., Zhang, F., Zhang, Y., Shan, H., Luo, X., Bai, Y., et al. (2010) · Circulation · doi:10.1161/circulationaha.110.958967 · Cited by 450
Beyer‐Westendorf, J., Förster, K., Pannach, S., Ebertz, F., Gelbricht, V., Thieme, C., Michalski, F., Köhler, C. U., Werth, S., Şahin, K., et al. (2014) · Blood · doi:10.1182/blood-2014-03-563577 · Cited by 408
Pernod, G., Albaladejo, P., Godiér, A., Samama, C. M., Susen, S., Gruel, Y., Blais, N., Fontana, P., Cohen, A. A., Llau, J. V., et al. (2013) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2013.04.009 · Cited by 310
Flagged first, then by citations
Research works printed but not linked: 1
- Crowther MA, 2013, J Thromb Haemost, 11, OC 20.1
Cited by
Sorted by citations
Items 501–600 of 1,000
Miller, D. J., Shah, K. B., Modi, S., Mahajan, A., Zahoor, S., & Affan, M. (2016) · Current Treatment Options in Neurology · doi:10.1007/s11940-016-0400-y · Cited by 9
Alcocer, L. A. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0163-6 · Cited by 9
Drug Treatment of Venous Thromboembolism in the Elderly
Boey, J. P., & Gallus, A. S. (2016) · Drugs & Aging · doi:10.1007/s40266-016-0378-x · Cited by 9
Müller, M. C. A., Stanworth, S. J., Coppens, M., & Juffermans, N. P. (2017) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2017.05.008 · Cited by 9
Reversal of dabigatran-associated bleeding using idarucizumab: review of the current evidence
Giustozzi, M., Verso, M., Agnelli, G., & Becattini, C. (2017) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-017-1555-4 · Cited by 9
How to prevent, recognize and manage complications of AF ablation?
Scanavacca, M. (2017) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2017.09.005 · Cited by 9
Mothers' experience of having children with diabetes.
Abolhassani, S., Babaee, S., & Eghbali‐Babadi, M. (2013) · Europe PMC (PubMed Central) · Cited by 9
Maragkos, G. Α., Nelton, E. B., Richter, S., & Stippler, M. (2020) · World Neurosurgery · doi:10.1016/j.wneu.2020.06.069 · Cited by 9
Auer, J., Huber, K., & Granger, C. B. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx416 · Cited by 9
Chen, G., Zhao, K., Li, M., Zhang, Y., Li, T., Yuan, J., Lü, L., Valdiviezo, J., Liu, D., Polizzi, N. F., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01404-w · Cited by 8
Martínez‐Rubio, A., Alcazar, M. D., Cadena, A. S., & Martínez-Torrecilla, R. (2016) · European Cardiology Review · doi:10.15420/ecr.2016:30:1 · Cited by 8
Lee, J., Joung, B., Cha, M., Lee, J. H., Lim, W., Kim, T., Shin, S. Y., Uhm, J., Lim, H. E., Kim, J., et al. (2018) · Korean Journal of Medicine · doi:10.3904/kjm.2018.93.2.87 · Cited by 8
Bekka, E., & Liakoni, E. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16142 · Cited by 8
Anticoagulation and Neuraxial/Peripheral Anesthesia
Kaushal, M., Rubin, R. E., Kaye, A. D., & Gritsenko, K. (2017) · Anesthesiology Clinics · doi:10.1016/j.anclin.2017.01.002 · Cited by 8
New anticoagulants for venous thromboembolism and atrial fibrillation: what the future holds
Dimitropoulos, G., Rahim, S., Moss, A. S., & Lip, G. Y. H. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1416090 · Cited by 8
Therapeutic Plasma Exchange for Urgent Rivaroxaban Reversal
Kumar, V. M., Allencherril, J., Bracey, A., Chen, A. J., & Lam, W. (2018) · Texas Heart Institute Journal · doi:10.14503/thij-17-6229 · Cited by 8
Andexanet Alfa for Reversing Factor Xa Inhibition
Sible, A. M., & Nawarskas, J. J. (2018) · Cardiology in Review · doi:10.1097/crd.0000000000000230 · Cited by 8
Greco, L., Zhang, J., & Ross, H. M. (2020) · Clinics in Colon and Rectal Surgery · doi:10.1055/s-0039-1693439 · Cited by 8
Use of direct oral anticoagulants in ICU patients. Part I – Applied pharmacology
Wahab, A., Patnaik, R., & Gurjar, M. (2021) · Anaesthesiology Intensive Therapy · doi:10.5114/ait.2021.110607 · Cited by 8
Abed, H. S., Chen, V. M. Y., Kilborn, M. J., & Sy, R. W. (2016) · Heart Lung and Circulation · doi:10.1016/j.hlc.2016.04.027 · Cited by 8
Management of Adult Traumatic Brain Injury: A Review
Janich, K., & Nguyen, H. S. (2016) · Journal of Trauma & Treatment · doi:10.4172/2167-1222.1000320 · Cited by 8
Introduction to direct oral anticoagulants and rationale for specific reversal agents
Pollack, C. V. (2016) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2016.09.045 · Cited by 8
Anticoagulant Reversal and Anesthetic Considerations
Meltzer, J. S., & Guenzer, J. R. (2017) · Anesthesiology Clinics · doi:10.1016/j.anclin.2017.01.005 · Cited by 8
Anticoagulation in Pulmonary Embolism: Update in the Age of Direct Oral Anticoagulants
Rosovsky, R. P. G., & Merli, G. J. (2017) · Techniques in vascular and interventional radiology · doi:10.1053/j.tvir.2017.07.003 · Cited by 8
Recent Advances in the Acute Management of Intracerebral Hemorrhage
Burns, J. D., Fisher, J. L., & Cervantes-Arslanian, A. M. (2017) · Neurologic Clinics · doi:10.1016/j.ncl.2017.06.009 · Cited by 8
A Review on the New and Old Anticoagulants
Myers, K., & Lyden, A. (2019) · Orthopaedic Nursing · doi:10.1097/nor.0000000000000517 · Cited by 8
Management of Anticoagulation and Antiplatelet Therapy in Glaucoma Surgery
Shukla, A. G., & Ramulu, P. Y. (2020) · Journal of Glaucoma · doi:10.1097/ijg.0000000000001594 · Cited by 8
Chang, W. C., Jackson, J. W., Machlus, K. R., Wolberg, A. S., & Ovanesov, M. V. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103077 · Cited by 8
Ticagrelor use and practice patterns among Canadian cardiac surgeons
Makhdoum, A., Dhingra, N. K., Kirubaharan, A., Eikelboom, R., Luc, J. G. Y., Dagher, O., Bierer, J. D., Cartier, A., Vaillancourt, O., Vo, T. X., et al. (2021) · Journal of Cardiac Surgery · doi:10.1111/jocs.15636 · Cited by 8
Two Cases of Acute Direct Oral Anticoagulant Overdose Without Adverse Effect
Ha, C. J., Harmouche, E., Howland, M. A., & Su, M. K. (2021) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000002263 · Cited by 8
Thromboprophylaxis in cancer patients in hospice
Zabrocka, E., Wojtukiewicz, M. Z., & Sierko, E. (2018) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/64593 · Cited by 8
Rivaroxaban in Chronic Hemodialysis Patients
Muster, H. A., & Alcorn, H. W. (2016) · American Journal of Nephrology · doi:10.1159/000445329 · Cited by 8
Levy, J. H., Shaw, J. R., Ghadimi, K., Maier, C. L., Douketis, J. D., Karkouti, K., Mazzeffi, M. A., Spyropoulos, A. C., Tanaka, K. A., Connors, J. M., et al. (2025) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2025.08.029 · Cited by 7
Detecting nonvalvular atrial fibrillation and anticoagulant therapy in cardioembolic ischemic stroke
Min, J., & Farooq, M. U. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1195236 · Cited by 7
Anästhesiologische Betreuung im orthogeriatrischen Co‑Management
Luger, T. J., & Luger, M. F. (2016) · Zeitschrift für Gerontologie und Geriatrie · doi:10.1007/s00391-016-1057-6 · Cited by 7
Novel Antithrombotic Agents in Pregnancy Anticoagulants and Antiplatelet Agents
James, A., Sugrue, R. P., & Federspiel, J. J. (2022) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000740 · Cited by 7
Shaw, J. R., Almujalli, A. A., Xu, Y., Levy, J. H., Schulman, S., Siegal, D. M., Dowlatshahi, D. D., Tokessy, M., Buyukdere, H., Carrier, M., et al. (2024) · Thrombosis Research · doi:10.1016/j.thromres.2024.109172 · Cited by 7
Self-citationAnticoagulants: From chance discovery to structure-based design
Chan, N., Carlin, S., & Hirsh, J. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100037 · Cited by 7
Iba, T., Emmi, M., Hiki, M., Nagayama, M., Aihara, K., Tabe, Y., Yuri, M., & Ohsaka, A. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-1975-5 · Cited by 7
Andexanet: Effectively Reversing Anticoagulation
Lippi, G., Sanchis‐Gomar, F., & Favaloro, E. J. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.03.002 · Cited by 7
Postoperative bleeding and coagulation disorders
Samama, C. M. (2016) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000317 · Cited by 7
Individualising Anticoagulant Therapy in Atrial Fibrillation Patients
Alings, M. (2016) · Arrhythmia & Electrophysiology Review · doi:10.15420/aer.2016.20.3 · Cited by 7
Trinh-Duc, A., Louët, A. L., Tellier, É., Viard, T., Gal, G. L., & Smadja, D. M. (2016) · Thrombosis Research · doi:10.1016/j.thromres.2016.08.014 · Cited by 7
Zalewski, J., & Undas, A. (2016) · Advances in Interventional Cardiology · doi:10.5114/aic.2016.63626 · Cited by 7
Clinical Implications of Reversal Agents for Direct Oral Anticoagulants
Monagle, S. R., Eikelboom, J. W., Ng, K. H., & Bhagirath, V. C. (2017) · Future Cardiology · doi:10.2217/fca-2016-0070 · Cited by 7
Edoxaban: How Does the Newest Agent Fit into the DOAC Landscape?
Gibson, C. M., & Finks, S. W. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.02.048 · Cited by 7
Sherrod, B. A., Condie, C. K., Brock, A. A., Ledyard, H. K., Menacho, S. T., & Mazur, M. D. (2019) · World Neurosurgery · doi:10.1016/j.wneu.2019.11.162 · Cited by 7
Anticoagulation Management in Patients With Atrial Fibrillation and Cirrhosis
Shenoy, A., Jarava, D., Stotts, M. J., & Intagliata, N. M. (2021) · Clinical Liver Disease · doi:10.1002/cld.1048 · Cited by 7
Aloysius, M. M. (2021) · Annals of Gastroenterology · doi:10.20524/aog.2021.0658 · Cited by 7
Andexanet alfa for reversal of rivaroxaban in a child with intracranial hemorrhage
Takasaki, K., Hehir, D. A., Raffini, L. J., Samelson‐Jones, B. J., Shih, E. K., & Dain, A. S. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.29484 · Cited by 7
Veldeman, M., Rossmann, T., Weiss, M., Conzen, C., Korja, M., Höllig, A., Virta, J. J., Satopää, J., Luostarinen, T., Clusmann, H., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041476 · Cited by 7
An update on the pharmaceutical management of thrombosis
Cosmi, B. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1241233 · Cited by 7
Novel (Oral) Anticoagulant Challenges in Surgery
Blennerhassett, R. C., Favaloro, E. J., & Pasalic, L. (2017) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0037-1602667 · Cited by 7
van der Pol, L. M., Mairuhu, A. T. A., Leroyer, C., Couturaud, F., Huisman, M., Klok, F. A., & Tromeur, C. (2018) · Seminars in Interventional Radiology · doi:10.1055/s-0038-1642622 · Cited by 7
Direct oral anticoagulants: peri‐operative considerations and controversies
Charlesworth, M., & Arya, R. (2018) · Anaesthesia · doi:10.1111/anae.14455 · Cited by 7
Chen, S.-J., Yeh, S., Tang, S., Lin, S., Tsai, L., & Jeng, J. (2019) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2019.02.008 · Cited by 7
Novel Oral Anticoagulants in Atrial Fibrillation: Update on Apixaban
Mezue, K. N., Obiagwu, C., John, J., Sharma, A., Yang, F., & Shani, J. (2016) · Current Cardiology Reviews · doi:10.2174/1573403x12666160720092024 · Cited by 7
Kocabaş, U., Kaya, E., & Avcı, G. (2016) · International Journal of the Cardiovascular Academy · doi:10.1016/j.ijcac.2016.08.006 · Cited by 7
Fibrilación auricular: enfoque para el médico no cardiólogo
de Caldas, U., Forero, J., Moreno, J., del Bosque, U., Agudelo, C. A., Cayre, I. P. S., Rodríguez, E., de Manizales, I. D. C., & Sánchez, P. (2017) · IATREIA · doi:10.17533/udea.iatreia.v30n4a05 · Cited by 7
Schmidt, K., Krüger, K., Langer, E., Schmutzler, M., Johnen, E., Wernecke, K. D., von Heymann, C., & Körber, M. K. (2019) · Blood transfusion · doi:10.2450/2018.0028-18 · Cited by 7
Advances in intracerebral hemorrhage management: A comprehensive review
Wang, S., Wang, J., Elmadhoun, O., Liang, Y., & Zhao, W. (2025) · Brain Circulation · doi:10.4103/bc.bc_177_24 · Cited by 6
A Systematic and Evidence-Based Review of Published and Pending Reports of Andexanet Alfa
Ellington, T. M. (2019) · Journal of Pharmacy Practice · doi:10.1177/0897190018822556 · Cited by 6
Harmouche, E., Stueve, P., Howland, M. A., & Su, M. K. (2023) · Journal of Pharmacy Practice · doi:10.1177/08971900231177570 · Cited by 6
Concha, M., Xu, L., Horn, M., Ohara, T., Nakamya, J., Beyer‐Westendorf, J., Shoamanesh, A., Cohen, A. T., Ladenvall, P., Connolly, S. J., et al. (2023) · Stroke Vascular and Interventional Neurology · doi:10.1161/svin.123.000997 · Cited by 6
Self-citationFasanya, C., Arrillaga, A., Caronia, C. G., Rothburd, L., Japhe, T., Hahn, Y., Joseph, P., Reci, D., & Eckardt, P. A. (2024) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296241238013 · Cited by 6
Rodrigues, A., Gonçalves, L. R., Gregório, T., Baldaia, C., Santo, G. C., & Gouveia, J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13226842 · Cited by 6
Neurologic Complications of Commonly Used Drugs in the Hospital Setting
Dawson, E. T., & Hocker, S. E. (2016) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-016-0636-7 · Cited by 6
Reversal of dabigatran by idarucizumab: when and how?
Vanassche, T., Greinacher, A., & Verhamme, P. B. (2016) · Expert Review of Hematology · doi:10.1080/17474086.2016.1184569 · Cited by 6
Reversal of Oral Anticoagulants for Intracerebral Hemorrhage Patients: Best Strategies
Fuh, L., Sin, J. H., Goldstein, J. N., & Hayes, B. D. (2017) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0037-1607993 · Cited by 6
Real world utilization of Andexanet Alfa at a community hospital
Santarelli, A., Dietrich, T., Sprague, R., Ajao, A., & Ashurst, J. V. (2020) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2020.11.043 · Cited by 6
Galhardo, C., Yamauchi, L. H. I., Dantas, H. V., & Guerra, J. C. D. C. (2021) · Brazilian Journal of Anesthesiology (English Edition) · doi:10.1016/j.bjane.2021.03.007 · Cited by 6
Ghenbot, Y. G., Arena, J. D., Howard, S., Wathen, C. A., Kumar, M. A., & Schuster, J. M. (2022) · World Neurosurgery X · doi:10.1016/j.wnsx.2022.100148 · Cited by 6
Wienhold, J., Rayatdoost, F., Schöchl, H., & Grottke, O. (2024) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000001349 · Cited by 6
Alturki, A. Y., Alamri, A., Badawy, M. K., & Teitelbaum, J. S. (2016) · World Neurosurgery · doi:10.1016/j.wneu.2016.02.070 · Cited by 6
Quick reference guide to the new oral anticoagulants
Hurst, K. V., Lee, R., & Handa, A. I. (2016) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2016.02.054 · Cited by 6
Hémorragie survenant chez un patient traité par un anticoagulant oral direct
Godiér, A., Martin, A., Rosencher, N., & Susen, S. (2016) · Journal des Maladies Vasculaires · doi:10.1016/j.jmv.2016.05.008 · Cited by 6
Kılıçkap, M., Bosch, J., Eikelboom, J. W., & Hart, R. G. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.06.003 · Cited by 6
Update on Anticoagulation: What the Interventional Radiologist Needs to Know
Kamath, S. D., & McMahon, B. J. (2016) · Seminars in Interventional Radiology · doi:10.1055/s-0036-1582124 · Cited by 6
Novel oral anticoagulant management issues for the stroke clinician
Wassef, A. M., & Butcher, K. (2016) · International Journal of Stroke · doi:10.1177/1747493016660100 · Cited by 6
Amiral, J., Dunois-Lardé, C., Amiral, C., & Seghatchian, J. (2016) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2016.09.003 · Cited by 6
Use of Rivaroxaban for Mesenteric Vein Thrombosis Secondary to Diverticulitis: A Case Report
Parthvi, R., & Mehra, S. (2016) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000512 · Cited by 6
Verzögerte Versorgung hüftgelenknaher Femurfrakturen
Ruffing, T., Haunschild, M., Egenolf, M., Eymann, W., Jost, D., Wallmen, G., & Burmeister, C. (2016) · Der Unfallchirurg · doi:10.1007/s00113-016-0243-8 · Cited by 6
Minguet, J., Sims, H. M., Smith, K. H., & Bramlage, P. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2016.1258301 · Cited by 6
DeAngelo, J., Jarrell, D. H., Cosgrove, R. H., Camamo, J. M., Edwards, C. J., & Patanwala, A. E. (2018) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp180076 · Cited by 6
Beginning to Understand the Cost-effectiveness of Andexxa
Haque, M., Gratson, M., Woerle, J., & Tavernier, F. (2019) · Georgetown Medical Review · doi:10.52504/001c.7777 · Cited by 6
Fan, K. L., Black, C. K., Abbate, O. A., Lu, K. B., Camden, R. C., & Evans, K. K. (2019) · Journal of Plastic Surgery and Hand Surgery · doi:10.1080/2000656x.2019.1650057 · Cited by 6
Assessment of the Patient With Intracerebral Hemorrhage
Kurian, C., Kaur, K., Kaur, G., & Sahni, R. (2020) · Cardiology in Review · doi:10.1097/crd.0000000000000332 · Cited by 7
Korbmacher, J. G., Schulze-Raestrup, U., Nowak, H., & Smektala, R. (2020) · Der Unfallchirurg · doi:10.1007/s00113-020-00923-2 · Cited by 6
Sibon, I., Mazighi, M., & Smadja, D. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2021.794001 · Cited by 6
Ammar, A. A., Elsamadicy, A. A., Ammar, M. A., Reeves, B. C., Koo, A. B., Falcone, G. J., Hwang, D. Y., Petersen, N., Kim, J. A., Beekman, R. B., et al. (2023) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2023.107621 · Cited by 6
Lenchus, J. D., Biehl, M., Cabrera, J. L., de Moraes, A. G., & Dezfulian, C. (2016) · Journal of Intensive Care Medicine · doi:10.1177/0885066616648265 · Cited by 6
Kasprzak, J. D., Dąbrowski, R., Barylski, M., Mamcarz, A., Wełnicki, M. T., Filipiak, K. J., Lodziński, P., Kozłowski, D., & Wożakowska−Kapłon, B. (2016) · Folia Cardiologica · doi:10.5603/fc.2016.0064 · Cited by 6
Perioperative management of patients with atrial fibrillation receiving anticoagulant therapy
Omae, T., Koh, K., Kumemura, M., Sakuraba, S., & Katsuda, Y. (2019) · Journal of Anesthesia · doi:10.1007/s00540-019-02653-1 · Cited by 6
Patel, R. B., & Tassiopoulos, A. K. (2019) · Advances in Surgery · doi:10.1016/j.yasu.2019.04.011 · Cited by 6
Patients on NOACs in the Emergency Room
Gerner, S. T., & Huttner, H. B. (2019) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-019-0954-7 · Cited by 6
Anticoagulation reversal for intracranial hemorrhage in the era of the direct oral anticoagulants
Strein, M., May, S., & Brophy, G. M. (2020) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000706 · Cited by 6
Martínez‐Rubio, A., & Dan, G. (2016) · European Cardiology Review · doi:10.15420/ecr.2016.11.2.ed2 · Cited by 6
Direct oral anticoagulants: a practical guide for the emergency physician
Hogg, K. E., Panag, A., Worster, A., & Thachil, J. V. (2016) · European Journal of Emergency Medicine · doi:10.1097/mej.0000000000000400 · Cited by 6
Ciraparantag for enoxaparin reversal: Adding to the evidence
Weitz, J. I., & Eikelboom, J. W. (2016) · Thrombosis Research · doi:10.1016/j.thromres.2016.08.013 · Cited by 6
Andexanet Alfa for Bleeding with Factor Xa Inhibitors
Ponnusamy, V., Sinha, A., & Kupfer, Y. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1906058 · Cited by 6
Metadata
- Authors
- Siegal, D. M., Curnutte, J. T., Connolly, S. J., Lu, G., Conley, P. B., Wiens, B. L., Mathur, V. S., Castillo, J., Bronson, M. D., Leeds, J. M., Mar, F. A., Gold, A., & Crowther, M. A.
- Affiliations
- Population Health Research Institute (CA)
- Portola Pharmaceuticals (United States) (US)
- McMaster University (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-12-17
- Volume
- 373
- Issue
- 25
- Pages
- 2413-2424
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2174386486
- Cited by
- 1,047
- References
- 22
- Citations by year
- 2026: 21 · 2025: 34 · 2024: 48 · 2023: 56 · 2022: 44 · 2021: 57 · 2020: 91 · 2019: 126 · 2018: 133 · 2017: 175 · 2016: 249 · 2015: 11
- FWCI
- 137.31
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Keywords
- andexanet alfa, factor Xa inhibitors, apixaban, rivaroxaban, anticoagulant reversal, bleeding complications, anti-Xa activity, thrombin generation, unbound drug concentration, D-dimer, prothrombin fragments, older adults, drug safety, pharmacokinetics, pharmacodynamics, thromboprophylaxis, thrombolysis
- MeSH terms
- Rivaroxaban, Administration, Oral, Aged, Antidotes, Blood Coagulation, Double-Blind Method, Female, Hemorrhage, Humans, Male, Middle Aged, Peptide Fragments, Protein Precursors, Prothrombin, Pyrazoles, Pyridones, Recombinant Proteins, Factor Xa, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
